Efficacy and tolerability of 12-weeks treatment with lipanthyl supra or trichol in Indonesian patients with dyslipidemia

The relation of dyslipidemia with the development and progression of atherosclerosis and coronary artery diseases has been demonstrated. This study compared the lipid modifying effects of locally-manufactured fenofibrate (trichol) versus lipanthyl supra in a randomized double-blind controlled study....

Full description

Saved in:
Bibliographic Details
Published in:Medical journal of Indonesia 2007-07, Vol.16 (3), p.159
Main Authors: Supari, Siti F., Raharjo, Sunu B., Liastuti, Lies D., Basha, Adnil
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relation of dyslipidemia with the development and progression of atherosclerosis and coronary artery diseases has been demonstrated. This study compared the lipid modifying effects of locally-manufactured fenofibrate (trichol) versus lipanthyl supra in a randomized double-blind controlled study. A total of sixty-eight patients with levels of HDL cholesterol ≤40 mg/dL; triglyceride of 200-600 mg/dL; or LDL of ≥130 mg/dL were recruited to this study and were randomized to either receive trichol 300 mg once daily or lipanthyl 160 mg once daily. Sixty one patients completed the study. Lipid levels before and 4, 8, and 12 weeks after the treatments were measured and analyzed. Compared to baseline values, 12-weeks treatment with either lipanthyl or trichol significantly increased plasma HDL by 18.8% and 14.3% respectively (P
ISSN:0853-1773
2252-8083
DOI:10.13181/mji.v16i3.273